SCHEMBL1270038

SCHEMBL1270038

O=S(=O)(c1ccccc1S)N1CCOCC1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.53
POLB P06746 3/20 0.53
MEN1 O00255 2/20 0.53
GAA P10253 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.52
NPC1 O15118 1/20 0.51
USP2 O75604 1/20 0.51
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
TSHR P16473 1/20 0.50
CYP2C19 P33261 1/20 0.50
ATM Q13315 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
ALOX5AP P20292 1/20 0.49
FEN1 P39748 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
ALDH1A1 P00352 2/20 0.49
LMNA P02545 2/20 0.49
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19259817 0.84 TSHR (0.71) KMT2APOLBMEN1GAAUSP2
SCHEMBL3247291 0.81 CNR1 (0.56) KMT2APOLBMEN1GAAL3MBTL1
SCHEMBL3343329 0.79 PKM (0.58) KMT2APOLBMEN1GAAL3MBTL1
SCHEMBL1956059 0.79 TSHR (0.55) KMT2APOLBMEN1GAAL3MBTL1
SCHEMBL28250596 0.79 ALDH1A1 (0.54) KMT2APOLBMEN1GAAL3MBTL1
SCHEMBL1911955 0.79 ALDH1A1 (0.63) KMT2APOLBMEN1GAAL3MBTL1
SCHEMBL30397969 0.79 POLB (0.53) KMT2APOLBMEN1GAAL3MBTL1
SCHEMBL2062548 0.79 POLB (0.53) KMT2APOLBMEN1GAAL3MBTL1
SCHEMBL20627051 0.79 POLB (0.53) KMT2APOLBMEN1GAAL3MBTL1
SCHEMBL21566685 0.79 ACHE (0.57) KMT2APOLBMEN1GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 US disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 EP disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 US disclosed
EP-1786782-A2 BISARYL-SULFONAMIDES Amgen Inc. (US) 2007-05-23 EP disclosed
US-20060084802-A1 Bisaryl-sulfonamides AMGEN INC. 2006-04-20 US disclosed
WO-2006020830-A2 BISARYL-SULFONAMIDES AMGEN INC. (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221584-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG KMT2A 1448/4885POLB 1629/4885MEN1 4841/4885
US-20060084802-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG KMT2A 1448/4885POLB 1629/4885MEN1 4841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.